Phosphagenics seeks listing on UK's AIM
Wednesday, 26 May, 2004
Melbourne-based Phosphagenics (ASX:POH) -– formerly Vital Capital -– has flagged its intention to seek a dual listing on the London Stock Exchange's Alternative Investment Market (AIM).
The company said in a statement that it believes the listing will provide access to a more developed capital market for the company’s globally orientated healthcare products
Investment bank Williams de Broë has been appointed as nominated adviser and stockbroker for the dual listing process.
Phosphagenics last month announced the successful completion of animal studies for its transdermal delivery system for morphine. The system uses d-alpha tocopherol combined with a phosophate molecule to create an enhanced form of Vitamin E which carries morphine across the dermis.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
